ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
ExcelFemale
HRT in Women
Hormone therapy in urogenital health after menopause
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 217211" data-attributes="member: 13851"><p><strong>Practice points </strong></p><p></p><p><em><strong>*Urogenital health in postmenopausal women deserves a proactive attitude of HCPs because early recognition is crucial to adequate management of VVA/GSM over time</strong></em></p><p><em><strong></strong></em></p><p><em><strong>*Both symptoms and signs are important in daily practice to make an accurate diagnosis and to establish the most suitable treatment plan </strong></em></p><p><em><strong></strong></em></p><p><em><strong>*Management should take into account individual risk factors and health issues, distress, impact on QOL and relationship, ability to maintain an active sex life, as well as women's needs and preferences</strong></em></p><p><em><strong></strong></em></p><p><em><strong>*Non-hormonal local therapy (lubricants and moisturizers) is the first-line strategy, especially in women with mild symptoms and contraindications, but it mitigates symptomatology without addressing the underlying pathological mechanisms</strong></em></p><p><em><strong></strong></em></p><p><em><strong>*In case of inadequate response to non-hormonal local therapy, and when women report moderate to severe VVA/GSM symptoms, HCPs should provide prescription medications </strong></em></p><p><em><strong></strong></em></p><p><em><strong>*Low-dose local estrogen therapy (LET) represents the first-line hormonal treatment and long-term data are available to prove efficacy and safety</strong></em></p><p><em><strong></strong></em></p><p><em><strong>*Intravaginal DHEA is an effective alternative to low-dose LET, but its dual estro-androgenic action deserves further studies to identify specific populations who may benefit most from its use</strong></em></p><p><em><strong></strong></em></p><p><strong><em>*Ospemifene is the only oral treatment with a selective action on VVA/GSM symptoms. Being a SERM, ospemifene is a promising option in BCS because of its neutral to antagonist effect on breast tissue, but its use is not currently recommended for BCS receiving ongoing treatment</em></strong></p></blockquote><p></p>
[QUOTE="madman, post: 217211, member: 13851"] [B]Practice points [/B] [I][B]*Urogenital health in postmenopausal women deserves a proactive attitude of HCPs because early recognition is crucial to adequate management of VVA/GSM over time *Both symptoms and signs are important in daily practice to make an accurate diagnosis and to establish the most suitable treatment plan *Management should take into account individual risk factors and health issues, distress, impact on QOL and relationship, ability to maintain an active sex life, as well as women's needs and preferences *Non-hormonal local therapy (lubricants and moisturizers) is the first-line strategy, especially in women with mild symptoms and contraindications, but it mitigates symptomatology without addressing the underlying pathological mechanisms *In case of inadequate response to non-hormonal local therapy, and when women report moderate to severe VVA/GSM symptoms, HCPs should provide prescription medications *Low-dose local estrogen therapy (LET) represents the first-line hormonal treatment and long-term data are available to prove efficacy and safety *Intravaginal DHEA is an effective alternative to low-dose LET, but its dual estro-androgenic action deserves further studies to identify specific populations who may benefit most from its use [/B][/I] [B][I]*Ospemifene is the only oral treatment with a selective action on VVA/GSM symptoms. Being a SERM, ospemifene is a promising option in BCS because of its neutral to antagonist effect on breast tissue, but its use is not currently recommended for BCS receiving ongoing treatment[/I][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
X (Twitter)
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
ExcelFemale
HRT in Women
Hormone therapy in urogenital health after menopause
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top